UK Leads European Research Programme with £10M Investment

The UK has made its first substantial commitment to a major emerging pan-European science project with a £10M investment by the Biotechnology and Biological Sciences Research Council (BBSRC). BBSRC has awarded funding to the European Molecular Biology Laboratory's European Bioinformatics Institute (EMBL-EBI), based at Hinxton near Cambridge, to permit a dramatic increase in the institute's data storage and handling capacity. The funding is the first step in developing the existing data resources and IT infrastructure of EMBL-EBI towards its planned role as the central hub of the emerging European Life-Science Infrastructure for Biological Information (ELIXIR), placing the UK at the forefront of this multinational initiative. The estimated total cost of establishing ELIXIR is significantly more than £200M.

Modern bioscience research, including the new generation of high through-put sequencing technologies, generates huge amounts of data. In order to use the data efficiently and to accelerate bioscience advances, such as the development of new drugs and therapies or higher yielding crops, scientists require better ways to deal with this avalanche of information.

ELIXIR is an initiative involving 32 partners from 13 countries aimed at establishing a sustainably funded infrastructure for biological information in Europe. It will support life science research and its applications to medicine, agriculture and food security, the environment, the bio-industries and society.

The UK's involvement in ELIXIR is supported by BBSRC, MRC, NERC and the Wellcome Trust.

EMBL-EBI Director and ELIXIR coordinator, Professor Janet Thornton, said: "The UK's decision to invest in ELIXIR is an important milestone in creating the infrastructure for biological information in Europe. The EBI will form the hub of a network of ELIXIR nodes that will empower European science at the interface of biology, computing and data management - one of the most vibrant areas of contemporary research. In particular it means that we will be able to implement next-generation datahandling and storage solutions, which will be able to cope with the flood of biological data and fuel future developments in basic biology, medicine, agriculture and environmental sciences."

Professor Doug Kell, Chief Executive of BBSRC, said: "Biology is an information science that is rich in data. UK science funders and EMBL-EBI are committed to ensuring that our researchers can use the latest computational technologies to store, access and analyse the huge amounts of data generated in contemporary bioscience, and thereby to turn them into knowledge and information. These data hold the key to tackling some of our most pressing challenges such as feeding an expanding world population, coping with climate change and providing new, high-efficacy therapeutics with minimal side effects. The UK will now be at the hub of an exciting European partnership to accelerate the application of science in these and other areas."

For further information, please visit:
http://www.ebi.ac.uk

About EMBL-EBI
The European Bioinformatics Institute (EBI) is a non-profit academic organisation that forms part of the European Molecular Biology Laboratory (EMBL).

The EBI is a centre for research and services in bioinformatics. The Institute manages databases of biological data including nucleic acid, protein sequences and macromolecular structures.

Most Popular Now

Herefordshire and Worcestershire Health …

Herefordshire and Worcestershire Health and Care NHS Trust has successfully implemented Alcidion's Miya Precision platform to streamline bed management workflow across seven community hospitals in Worcestershire. The trust delivers community...

A Shortcut for Drug Discovery

For most human proteins, there are no small molecules known to bind them chemically (so called "ligands"). Ligands frequently represent important starting points for drug development but this knowledge gap...

New Horizon Europe Funding Boosts Europe…

The European Commission has announced the launch of new Horizon Europe calls, with a substantial funding pool of over €112 million. These calls are aimed primarily at pioneering projects in...

Cleveland Clinic Study Finds AI can Deve…

Cleveland Clinic researchers developed an artficial intelligence (AI) model that can determine the best combination and timeline to use when prescribing drugs to treat a bacterial infection, based solely on...

New AI-Technology Estimates Brain Age Us…

As people age, their brains do, too. But if a brain ages prematurely, there is potential for age-related diseases such as mild-cognitive impairment, dementia, or Parkinson's disease. If "brain age...

With Huge Patient Dataset, AI Accurately…

Scientists have designed a new artificial intelligence (AI) model that emulates randomized clinical trials at determining the treatment options most effective at preventing stroke in people with heart disease. The model...

Radboud University Medical Center and Ph…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud University Medical Center have signed a hospital-wide, long-term strategic partnership that delivers the latest patient monitoring...

GPT-4, Google Gemini Fall Short in Breas…

Use of publicly available large language models (LLMs) resulted in changes in breast imaging reports classification that could have a negative effect on patient management, according to a new international...

ChatGPT fails at heart risk assessment

Despite ChatGPT's reported ability to pass medical exams, new research indicates it would be unwise to rely on it for some health assessments, such as whether a patient with chest...

Study Shows ChatGPT Failed when Challeng…

With artificial intelligence (AI) poised to become a fundamental part of clinical research and decision making, many still question the accuracy of ChatGPT, a sophisticated AI language model, to support...

Virtual Reality Shows Promise in Fightin…

A new study published in JMIR Mental Health sheds light on the promising role of virtual reality (VR) in treating major depressive disorder (MDD). Titled "Examining the Efficacy of Extended...

AXREM and Highland Marketing Partner to …

AXREM represents member companies that collectively provide UK hospitals with most of their diagnostic medical imaging technology, and radiotherapy equipment. The association has seen substantial growth in recent years, with membership...